Chromadex (CDXC) Raised to Hold at BidaskClub

BidaskClub upgraded shares of Chromadex (NASDAQ:CDXC) from a sell rating to a hold rating in a research report sent to investors on Friday.

CDXC has been the topic of several other research reports. HC Wainwright set a $8.00 target price on shares of Chromadex and gave the stock a buy rating in a report on Friday, December 15th. Zacks Investment Research cut shares of Chromadex from a buy rating to a hold rating in a report on Wednesday, November 29th. Finally, ValuEngine downgraded shares of Chromadex from a hold rating to a sell rating in a research report on Friday, December 1st. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Chromadex has an average rating of Hold and a consensus price target of $7.50.

Shares of Chromadex (CDXC) opened at $5.07 on Friday. Chromadex has a fifty-two week low of $2.26 and a fifty-two week high of $7.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 4.12. The stock has a market cap of $272.96, a P/E ratio of -36.21 and a beta of 1.03.

Chromadex (NASDAQ:CDXC) last issued its earnings results on Thursday, November 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.02). Chromadex had a negative return on equity of 47.30% and a negative net margin of 21.89%. The company had revenue of $6.09 million during the quarter, compared to analysts’ expectations of $6.50 million. analysts expect that Chromadex will post -0.15 EPS for the current fiscal year.

In other Chromadex news, CEO Frank L. Jaksch, Jr. sold 58,400 shares of the stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $6.19, for a total value of $361,496.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Frank L. Jaksch, Jr. sold 28,379 shares of the stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $6.52, for a total transaction of $185,031.08. The disclosure for this sale can be found here. 11.59% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CDXC. Goldman Sachs Group Inc. raised its position in Chromadex by 870.6% in the second quarter. Goldman Sachs Group Inc. now owns 182,633 shares of the company’s stock worth $698,000 after acquiring an additional 163,817 shares during the period. Oppenheimer & Co. Inc. bought a new position in Chromadex in the fourth quarter worth approximately $250,000. Wells Fargo & Company MN raised its position in Chromadex by 370.4% in the fourth quarter. Wells Fargo & Company MN now owns 51,747 shares of the company’s stock worth $304,000 after acquiring an additional 40,747 shares during the period. Thompson Davis & CO. Inc. bought a new position in Chromadex in the third quarter worth approximately $128,000. Finally, Cetera Advisor Networks LLC bought a new position in Chromadex in the fourth quarter worth approximately $147,000. Institutional investors and hedge funds own 5.87% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Chromadex (CDXC) Raised to Hold at BidaskClub” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://stocknewstimes.com/2018/02/12/chromadex-cdxc-raised-to-hold-at-bidaskclub.html.

Chromadex Company Profile

Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply